Latest news
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - StocktwitsStocktwits · Sat, 08 Aug 2026 08:07:36 GMTOral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 16:04:43 GMTChina's Innocare says psoriasis oral drug shows 'consistent treatment effect' in late-stage trial - ET PharmaET Pharma · Tue, 28 Jul 2026 07:00:00 GMT